Scotiabank raises Methanex stock price target on methanol outlook By Investing.com

Scotiabank raised Methanex’s price target to $80 from $70 and kept a Sector Outperform rating, citing stronger methanol pricing and constrained Iranian exports. It lifted 2026/2027 EBITDA estimates to $1.67B and $1.37B, and expects Q2 EBITDA of $565M using the top end of guidance. The firm also sees leverage falling to 2.5x by quarter-end, potentially enabling share repurchases in the second half of 2026.

Analysis

The clean read-through is that this is less a “methanol is good” story and more a balance-sheet optionality catalyst. When a commodity producer de-risks leverage into the mid-2s, equity rerating can happen before the market fully updates terminal pricing, because the next marginal buyer is often a capital-return cohort rather than a commodity-call buyer. That means the stock’s upside is increasingly tied to free cash flow durability, not just spot methanol, which is typically a better setup for multiple expansion in the next 3-6 months.

The second-order beneficiary is anyone exposed to constrained global methanol availability, but the more important competitive effect is on cost discipline across the industry. If the supply backdrop stays tight, higher-cost or more levered producers will be forced to choose between preserving volume and preserving margin, which can create a sharper spread between low-cost names and the rest of the pack over the next two reporting cycles. The market is also implicitly treating geopolitical supply risk as persistent; that tends to support forward curves until a visible re-route of volumes appears.

The main risk is that the current setup is highly consensus-sensitive: if Iranian volumes normalize even modestly, the market can reprice the entire 2026-2027 earnings stack quickly, because the valuation is now anchored to a relatively high EBITDA multiple on future cash flows. Another reversal trigger is oil/natural gas weakness, which would compress producer economics and undermine the “demand-driven” narrative. On timing, the next 1-2 quarters matter more than the next 1-2 years because the buyback thesis only becomes self-reinforcing once leverage is clearly trending toward the target.

The contrarian angle is that the move may be underreacting to capital return optionality but overreacting to the permanence of the supply constraint. If debt paydown proceeds faster than expected, the equity can re-rate on buyback capacity alone; if not, the stock becomes a levered proxy for a commodity thesis that can unwind fast. For JPM, the signal is marginally negative in the sense that this reinforces the market’s preference for better capital discipline and clearer balance-sheet paths in cyclical industrials, which can widen relative-performance dispersion across the coverage universe.

Key Decisions for Investors

• Long MX on weakness over the next 1-3 weeks, targeting a 10-15% move as the market prices in near-term deleveraging and buyback optionality; risk is a 5-7% pullback if commodity sentiment softens.
• Buy MX Jan/Apr call spreads to express a 3-6 month rerating thesis while limiting downside to premium paid; structure for a move that benefits from both multiple expansion and forecast revisions.
• Pair trade: long MX / short a higher-leverage methanol-linked producer or chemical cyclical basket over 1-2 quarters to capture spread widening if tight supply persists and balance-sheet quality matters more than spot beta.
• Use JPM only as a small relative-value short against select capital-return winners if the market keeps rewarding “self-help” balance sheets; this is a dispersion trade, not a directional macro call.
• Take profits into any sharp pre-earnings run-up if MX trades materially above the implied valuation range without a corresponding upward revision in free cash flow or leverage trajectory; the risk/reward deteriorates quickly once the buyback story is fully in the price.